Octreotide Acetate & Product use in unapproved indication

34.8%

of users reported Product use in unapproved indication

51.6%

also reported Hospitalization

52.3%

are women

Hospitalization

51.6%

Severe reaction

39.1%

Death

4.7%

Life-threatening condition

4.7%

Octreotide Acetate: general information

50 - 59 years

8.6%

60 - 69 years

31.0%

70 - 79 years

44.4%

80 - 89 years

15.9%